NRAS or KRAS point mutations have been described in 25% of patients with JMML [29], and apart from a small portion of NRAS-mutated patients, somatic RAS mutations are usually associated with an aggressive disease course with a high rate of relapse after HSCT [5]. Here, KRAS is linked to juvenile myelomonocytic leukemia.